Acne
Anxiety
Depression
Hair-Loss
Nutrition-2
Supplements
Weight-Loss-4
Acne-2
Asthma
Diabetes
Hair-Loss-2
Nutrition-3
Weight-Loss
Weight-Loss-5
Acne-3
Bird-Flu
Diet
Mental-Health
Nutrition-4
Weight-Loss-2
Womens-Health
Alternative
Dental
Diet-2
Nutrition
Pregnancy
Weight-Loss-3
|
|
Acomplia Claims to Treat Tobacco Dependence |
Obesity is becoming a cosmopolitan problem. It has created some major health related hazards globally like diabetes, chronic heart diseases, high blood pressure etc. In some nations like US and UK, it is a prevailing disease among both adults and children. The causes of obesity are considered a multifactoral problem. Some major factors which are involved for the cause of obesity are like eating disorders, no physical activity, and most important is the habit of smoking.
A continuous research on finding a concrete solution, most dieticians came to the decision that Diet pills can be very significant for eliminating obesity significantly. Sometimes what happens even under a controlled diet and a vigorous exercise regimen, a person cannot attain the desired result. In such case a diet pill seems to work more effectively. In this context, Acomplia diet pill is the next hot thing that is gaining popularity in the weight loss industry. The drug is proved to be well tolerated and mild. The only relatively common side affects are mild gastro intestinal side affects with some dizziness and these are found to be transient.
Acomplia is an effective form of therapy for obese patients who need to lose weight as well as decrease diseases associated with obesity. But the degree of the weight loss through Acomplia will depend on the rate of caloric restriction and the use of a graded exercise schedule. So, it should be combined with a healthy lifestyle including physical activity and improved diet to lose and maintain weight successfully over the long term.
Acomplia, also known as Rimonabant, has shown promise in a half-dozen clinical trials in curbing the cravings that make people hungry and reach for a cigarette. It’s the first new class drug which blocks selective CB1 receptors. This drug works by inhibiting the CB1 receptor found in the Endocannabinoid system or EC system that are located in the brain. Apart from its association with body’s regulation of the body’s intake of food, EC system is also found to be associated with one’s tobacco dependency. By blocking the CB1 receptor, Acomplia helps restore balance to the EC system resulting in reduced dependence on tobacco and stops unnecessary hunger for food.
A product from Sanofi-Aventis is a completely new treatment for obesity. Besides, experiments are going on for FDA approval. This dual benefit, smoking cessation and reduced obesity is going to make Acomplia a promising agent for treating tobacco dependence.
Jack White is an associated editor to AcompliaRimonabant. He is a contributing author and provides information on General Health related issues. For more details related to Acomplia Rimonabant, Xenical, Reductil, Lipograsil, Slim 24, Turbo Slim Men visit www.acompliarimonabant.co.uk |
|
| |
|
